MAP2K7 and cutaneous melanoma: Several large phase 3 randomized studies in cutaneous melanoma with BRAFV600E mutations [49,50,51] revealed the advantages of a combination of MEK inhibitors (Cobimetinib or Trametenib) with BRAF inhibitors (Dabrafenib or Vemurafenib) over monotherapy with the BRAF inhibitor.